Walker, Nicolas J.
Rashid, Mamunur
Yu, Shirong
Bignell, Helen
Lumby, Casper K.
Livi, Carmen M.
Howell, Kate
Morley, David J.
Morganella, Sandro
Barrell, Daniel
Caim, Shabhonam
Gosal, Walraj
Füllgrabe, Jens
Charlesworth, Thomas J.
Vasquez, Louella
Ahdesmäki, Miika
Eizenga, Jordan
Prabhat, Parul
Proutski, Vitali
Murat-Onana, Marie Laurie
Greenwood, Catherine J.
Kirkwood, Lisa
Maisuria-Armer, Meeta
Li, Mengjie
Coats, Emma
Winfield, Victoria
MacBean, Lachlan
Stock, Toby
Tomé-Fernandez, Alice
Chan, Yat
Sheikh, Nasir
Golder, Paula
Steward, Michael
Ost, Tobias W. B.
Stewart, Douglas
Vilella, Albert
Noursalehi, Mojtaba
Paten, Benedict
Lucarelli, Debora
Mason, Joanne
Ridge, Gareth
Mellad, Jason
Shirodkar, Suman
Balasubaramanian, Shankar
Holbrook, Joanna D.
Article History
Received: 15 November 2021
Accepted: 21 September 2022
First Online: 4 October 2022
Competing interests
: SC, MR, CML, CKL, KH, SM, NJW, LV, MA, MN, TO, HB, SY, JDH, DL, EC and MS are named inventors to patent applications filed by Cambridge Epigenetix Limited pertaining to one or more aspects of the technologies described herein. SY, CKL, DJM, WG, JF, TC, and JDH are current employees of Cambridge Epigenetix Limited. SM, BP, JE, SB and MN have received consulting fees from Cambridge Epigenetix Limited. NJW, MR, SY, CKL, CML, KH, DJM, WG, JF, TC, HB, GR, SB, SC, ML, YC, CJ, LK, MMA, EC, VW, LM, TB, ATF, NS, PG, MK, SM, LV, SS, MA, DB, MJ, DL, JM, MS, TO, VP, MM, DS, AV, SB and JDH have rights to share options in Cambridge Epigenetix Limited.